MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic ...
Jan 11, 2021
0
11
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving ...
Jun 2, 2011
0
0
Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors. The body has two ...
Jan 5, 2017
0
1
Researchers at McGill University have discovered that a key regulator of energy metabolism in cancer cells known as the AMP-activated protein kinase (AMPK) may play a crucial role in restricting cancer cell growth. AMPK acts ...
Dec 27, 2012
0
0
A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs ...
Oct 27, 2022
0
34
When University of Colorado Cancer Center researcher, Jing Hong Wang, MD, PhD, found more than 1,000 genetic translocations in her mouse model of B cell lymphoma, she assumed her lab had made a mistake. To rule out experimental ...
Oct 27, 2016
0
42
Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery. A team at the Max Delbrück Center led by Professor Claus Scheidereit has now identified an important ...
May 14, 2019
0
6
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller ...
Dec 10, 2020
0
84
Two cancer immunotherapies have been reviewed for NHS use in Scotland.
Feb 13, 2019
0
3
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous ...
Dec 7, 2015
0
0
